Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTR-ACT tafamidis in transthyretin cardiomyopathy
2012-002465-35Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tafamidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM) (3 arms), sponsored by Pfizer. Primary endpoints: Primary endpoint: all-cause mortality, Primary endpoint: frequency of cardiovascular-related hospitalizations and 1 more. Started Dec 2013; status: completed.
02
Drugs
tafamidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2012-002465-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002465-35.